CA Patent

CA2159629A1 — Oligonucleotides with amide linkages replacing phosphodiester linkages

Assigned to Sanofi SA · Expires 1994-10-13 · 32y expired

What this patent protects

Disclosed are oligonucleotide analogs comprising olignucleoside sequences having from 3 to about 200 bases and containing internucleoside linkages wherein amide linkages replace phosphodiester linkages that are the backbones of the natural oligonucleotides that make up RNA and DN…

USPTO Abstract

Disclosed are oligonucleotide analogs comprising olignucleoside sequences having from 3 to about 200 bases and containing internucleoside linkages wherein amide linkages replace phosphodiester linkages that are the backbones of the natural oligonucleotides that make up RNA and DNA. Also disclosed are bifunctional nucleoside analogs, a process for preparing dimers and trimers therefrom, and a method of using these bifunctional nucleoside intermediates, including the dimers and trimers, to synthesize the above-described oligonucleotide analogs using conventional synthetic organic procedures known in the art, preferably in a solid phase synthesis, more preferably in an automated peptide synthesizer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2159629A1
Jurisdiction
CA
Classification
Expires
1994-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.